This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameBetulinic Acid
Accession NumberDB12480  (DB05910)
TypeSmall Molecule
GroupsInvestigational
Description

Betulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.

Structure
Thumb
Synonyms
beta-betulinic acid
External IDs ALS-357 / NSC-113090
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNII4G6A18707N
CAS number472-15-1
WeightAverage: 456.711
Monoisotopic: 456.360345406
Chemical FormulaC30H48O3
InChI KeyQGJZLNKBHJESQX-FZFNOLFKSA-N
InChI
InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
IUPAC Name
(1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-17-hydroxy-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0²,¹⁰.0⁵,⁹.0¹⁴,¹⁹]henicosane-5-carboxylic acid
SMILES
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabBetulinic Acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololBetulinic Acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Betulinic Acid.Approved
AcenocoumarolBetulinic Acid may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Betulinic Acid.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Betulinic Acid.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Betulinic Acid.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Betulinic Acid.Approved, Vet Approved
AclarubicinBetulinic Acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Betulinic Acid.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Alendronic acid.Approved
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Betulinic Acid.Approved, Vet Approved
AliskirenBetulinic Acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololBetulinic Acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Betulinic Acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Amcinonide.Approved
AmikacinBetulinic Acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideBetulinic Acid may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinBetulinic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodBetulinic Acid may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Betulinic Acid.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Anisodamine.Investigational
annamycinBetulinic Acid may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Betulinic Acid.Approved
Antithrombin III humanBetulinic Acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanBetulinic Acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Acetovanillone.Investigational
ApramycinBetulinic Acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Betulinic Acid.Approved, Investigational
ArbekacinBetulinic Acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinBetulinic Acid may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanBetulinic Acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololBetulinic Acid may decrease the antihypertensive activities of Arotinolol.Approved
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Betulinic Acid.Approved
AtenololBetulinic Acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Betulinic Acid.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Betulinic Acid.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Betulinic Acid.Approved
BalsalazideBetulinic Acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminBetulinic Acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololBetulinic Acid may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Betulinic Acid.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Betulinic Acid.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Betulinic Acid.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Betulinic Acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Betamethasone.Approved, Vet Approved
BetaxololBetulinic Acid may decrease the antihypertensive activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Betulinic Acid.Approved, Investigational
BevantololBetulinic Acid may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Betulinic Acid.Approved, Investigational
BisoprololBetulinic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinBetulinic Acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Betulinic Acid.Investigational
BopindololBetulinic Acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Betulinic Acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Betulinic Acid.Investigational
BucindololBetulinic Acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Budesonide.Approved
BufuralolBetulinic Acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideBetulinic Acid may decrease the diuretic activities of Bumetanide.Approved
BupranololBetulinic Acid may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Betulinic Acid.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Betulinic Acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Betulinic Acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Betulinic Acid.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Betulinic Acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Betulinic Acid.Approved, Vet Approved, Withdrawn
CarteololBetulinic Acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolBetulinic Acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Betulinic Acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Celecoxib.Approved, Investigational
CeliprololBetulinic Acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinBetulinic Acid may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Betulinic Acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Betulinic Acid.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Betulinic Acid.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Betulinic Acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Betulinic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Betulinic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Betulinic Acid.Approved
CinoxacinBetulinic Acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinBetulinic Acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidBetulinic Acid may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Betulinic Acid.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Betulinic Acid.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Betulinic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Betulinic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Betulinic Acid.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Betulinic Acid.Approved, Investigational
CyclosporineBetulinic Acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Betulinic Acid.Investigational
Dabigatran etexilateBetulinic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinBetulinic Acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBetulinic Acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapsoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Dapsone.Approved, Investigational
DarexabanBetulinic Acid may increase the anticoagulant activities of Ym150.Investigational
DaunorubicinBetulinic Acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Deferasirox.Approved, Investigational
DesirudinBetulinic Acid may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Betulinic Acid.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Betulinic Acid.Approved
DextranBetulinic Acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Betulinic Acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Betulinic Acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Betulinic Acid may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Betulinic Acid.Approved, Vet Approved
DicoumarolBetulinic Acid may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Betulinic Acid.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Betulinic Acid.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Betulinic Acid.Approved
DihydrostreptomycinBetulinic Acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Betulinic Acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Betulinic Acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Betulinic Acid.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Betulinic Acid.Approved, Investigational
DoxorubicinBetulinic Acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneBetulinic Acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Betulinic Acid.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Betulinic Acid.Investigational
E-6201The risk or severity of adverse effects can be increased when E6201 is combined with Betulinic Acid.Investigational
EbselenThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Ebselen.Investigational
Edetic AcidBetulinic Acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBetulinic Acid may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Betulinic Acid.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Betulinic Acid.Approved
EnoxacinBetulinic Acid may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinBetulinic Acid may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Betulinic Acid.Approved
EpirubicinBetulinic Acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneBetulinic Acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Betulinic Acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Betulinic Acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Equilin.Approved
EsmololBetulinic Acid may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Estrone sulfate.Approved
Etacrynic acidBetulinic Acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Betulinic Acid.Approved, Investigational
Ethyl biscoumacetateBetulinic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Betulinic Acid.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Betulinic Acid.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Betulinic Acid.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Betulinic Acid.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Betulinic Acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Betulinic Acid.Vet Approved
FleroxacinBetulinic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Betulinic Acid.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fludrocortisone.Approved
FluindioneBetulinic Acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineBetulinic Acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Betulinic Acid.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluorometholone.Approved
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Betulinic Acid.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Betulinic Acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Betulinic Acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Betulinic Acid.Approved, Nutraceutical, Vet Approved
FondaparinuxBetulinic Acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumBetulinic Acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Betulinic Acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Betulinic Acid.Approved
FramycetinBetulinic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideBetulinic Acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateBetulinic Acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinBetulinic Acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinBetulinic Acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Betulinic Acid.Approved, Withdrawn
GemifloxacinBetulinic Acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinBetulinic Acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinBetulinic Acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ABetulinic Acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinBetulinic Acid may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Betulinic Acid is combined with HE3286.Investigational
HeparinBetulinic Acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Higenamine.Investigational
HydralazineBetulinic Acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Betulinic Acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Betulinic Acid.Approved
Hygromycin BBetulinic Acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Betulinic Acid.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Betulinic Acid.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Betulinic Acid.Approved
IdarubicinBetulinic Acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxBetulinic Acid may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Betulinic Acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Betulinic Acid.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Betulinic Acid.Approved
IndenololBetulinic Acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Betulinic Acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Betulinic Acid.Withdrawn
INNO-206Betulinic Acid may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Betulinic Acid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Betulinic Acid.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Istaroxime.Investigational
KanamycinBetulinic Acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Betulinic Acid.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Betulinic Acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Betulinic Acid.Approved
LabetalolBetulinic Acid may decrease the antihypertensive activities of Labetalol.Approved
LandiololBetulinic Acid may decrease the antihypertensive activities of Aop200704.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Betulinic Acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Betulinic Acid.Approved, Investigational
LepirudinBetulinic Acid may increase the anticoagulant activities of Lepirudin.Approved
LevobunololBetulinic Acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinBetulinic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Betulinic Acid.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Betulinic Acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Betulinic Acid.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Betulinic Acid.Approved
LomefloxacinBetulinic Acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Betulinic Acid.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Betulinic Acid.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Betulinic Acid.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Betulinic Acid.Approved, Investigational
LumefantrineThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Betulinic Acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Betulinic Acid.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Betulinic Acid.Approved
ME-609The risk or severity of adverse effects can be increased when Betulinic Acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betulinic Acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Betulinic Acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Betulinic Acid.Approved, Vet Approved
MesalazineBetulinic Acid may increase the nephrotoxic activities of Mesalazine.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Betulinic Acid.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Betulinic Acid.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Betulinic Acid.Approved
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Betulinic Acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Betulinic Acid.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Betulinic Acid.Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololBetulinic Acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Betulinic Acid.Approved
MetoprololBetulinic Acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideBetulinic Acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Betulinic Acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Betulinic Acid.Approved
MometasoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Mometasone.Approved, Vet Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Betulinic Acid.Approved, Withdrawn
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Betulinic Acid.Approved
MoxifloxacinBetulinic Acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Betulinic Acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Betulinic Acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Nabumetone.Approved
NadololBetulinic Acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinBetulinic Acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatBetulinic Acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Betulinic Acid.Approved
Nalidixic AcidBetulinic Acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Betulinic Acid.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Betulinic Acid is combined with NCX 1022.Investigational
NeamineBetulinic Acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinBetulinic Acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinBetulinic Acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Betulinic Acid.Approved
NetilmicinBetulinic Acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Betulinic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Betulinic Acid.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Nitroaspirin.Investigational
NorfloxacinBetulinic Acid may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinBetulinic Acid may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Betulinic Acid.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Betulinic Acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Betulinic Acid.Approved
OlsalazineBetulinic Acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Betulinic Acid.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Betulinic Acid.Vet Approved
OtamixabanBetulinic Acid may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Betulinic Acid.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Betulinic Acid.Approved
OxprenololBetulinic Acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Betulinic Acid.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Betulinic Acid.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Parecoxib.Approved
ParomomycinBetulinic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinBetulinic Acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinBetulinic Acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololBetulinic Acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateBetulinic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Betulinic Acid.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Betulinic Acid.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Betulinic Acid.Approved
PhenindioneBetulinic Acid may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonBetulinic Acid may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Betulinic Acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Betulinic Acid.Approved, Investigational
PindololBetulinic Acid may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinBetulinic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideBetulinic Acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Betulinic Acid.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Betulinic Acid.Approved, Investigational
PlicamycinBetulinic Acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Betulinic Acid.Approved
PractololBetulinic Acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Betulinic Acid.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with dehydroepiandrosterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Betulinic Acid can be increased when it is combined with Probenecid.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Betulinic Acid.Approved, Vet Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Betulinic Acid.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Betulinic Acid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Betulinic Acid.Approved
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Betulinic Acid.Vet Approved
PropranololBetulinic Acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Betulinic Acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Betulinic Acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Betulinic Acid.Vet Approved
Protein CBetulinic Acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanBetulinic Acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBetulinic Acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinBetulinic Acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Betulinic Acid.Investigational
PuromycinBetulinic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Betulinic Acid.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Betulinic Acid.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Betulinic Acid.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Betulinic Acid.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Betulinic Acid.Experimental, Investigational
ReviparinBetulinic Acid may increase the anticoagulant activities of Reviparin.Approved
RibostamycinBetulinic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Risedronate.Approved, Investigational
RivaroxabanBetulinic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinBetulinic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Betulinic Acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Betulinic Acid.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Betulinic Acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Betulinic Acid.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Betulinic Acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Betulinic Acid.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Betulinic Acid.Approved
SisomicinBetulinic Acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolBetulinic Acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CBetulinic Acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinBetulinic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinBetulinic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Betulinic Acid.Approved
SpironolactoneBetulinic Acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Betulinic Acid.Investigational
StreptomycinBetulinic Acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinBetulinic Acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineBetulinic Acid may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Betulinic Acid.Approved
SulodexideBetulinic Acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Betulinic Acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Betulinic Acid.Approved, Withdrawn
TacrolimusBetulinic Acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Betulinic Acid.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Betulinic Acid.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Betulinic Acid.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Betulinic Acid.Approved, Investigational
TemafloxacinBetulinic Acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Betulinic Acid.Experimental, Investigational
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Betulinic Acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Betulinic Acid.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Betulinic Acid.Approved
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Betulinic Acid.Withdrawn
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Betulinic Acid.Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Betulinic Acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Tiludronate.Approved, Vet Approved
TimololBetulinic Acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Tixocortol.Approved
TobramycinBetulinic Acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Betulinic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Betulinic Acid.Approved
TorasemideBetulinic Acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Betulinic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Betulinic Acid.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Betulinic Acid.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Betulinic Acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Betulinic Acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneBetulinic Acid may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Betulinic Acid.Approved, Vet Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Betulinic Acid.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Betulinic Acid.Approved, Vet Approved
TrovafloxacinBetulinic Acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Betulinic Acid.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinBetulinic Acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Betulinic Acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Betulinic Acid.Approved
WarfarinBetulinic Acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBetulinic Acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Betulinic Acid.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Betulinic Acid.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Betulinic Acid.Withdrawn
ZorubicinBetulinic Acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Unknown StatusTreatmentMelanoma1
1, 2SuspendedTreatmentDysplastic Nevus Syndrome1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000204 mg/mLALOGPS
logP5.34ALOGPS
logP6.64ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)4.75ChemAxon
pKa (Strongest Basic)-0.84ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity132.63 m3·mol-1ChemAxon
Polarizability54.64 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , negativesplash10-004i-0019400000-d634f687c0b20b3bf518View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , negativesplash10-004i-0019400000-946b3acbf03ebc325984View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , negativesplash10-06vi-0009700000-133d884e7fe1aabfb659View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , negativesplash10-06vr-0019800000-a2c226a96551460f31b8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , negativesplash10-0a4i-0000411190-9e794d71d8e215a3ef7fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , negativesplash10-0a4i-0000511290-00b42fd32f4bea1aac24View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-004i-0009100000-02c4ffe35137e2459ef9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-004i-0009100000-b369b92782bf0058f776View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-0udi-0000900000-31877b3328749253f478View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-0udi-0000900000-46226c91dca257ecbdbeView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-004i-0119300000-d165dda7f84c911bb084View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-004i-0119400000-c8efa7eb386af139bbbbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-0udi-0000900000-5daf110b6535ef5e1cbaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-0udi-0000900000-1a6ea554c157db014b7cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-01p9-0000900000-95cc62b5cf4bd28b6108View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Linear Ion Trap , positivesplash10-01p9-0000900000-1a328cc168bc37caf6d7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0a4r-0920300000-e3035523b40f714793c7View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as triterpenoids. These are terpene molecules containing six isoprene units.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassTriterpenoids
Direct ParentTriterpenoids
Alternative Parents18-hydroxysteroids / Oxosteroids / Secondary alcohols / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
SubstituentsTriterpenoid / 18-oxosteroid / 18-hydroxysteroid / Oxosteroid / Hydroxysteroid / Steroid / Cyclic alcohol / Secondary alcohol / Monocarboxylic acid or derivatives / Carboxylic acid
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptorshydroxy monocarboxylic acid, pentacyclic triterpenoid (CHEBI:3087 ) / Lupanes (C08619 ) / Lupane triterpenoids (LMPR0106140004 )
Drug created on October 20, 2016 16:33 / Updated on September 01, 2017 12:21